BioNTech SE (BVMF:B1NT34)

Market Cap	142.90B
Revenue (ttm)	19.71B
Net Income (ttm)	-3.57B
Shares Out	n/a
EPS (ttm)	-14.91
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	182
Average Volume	693
Open	33.36
Previous Close	33.12
Day's Range	33.36 - 33.42
52-Week Range	30.80 - 47.30
Beta	1.41
RSI	64.39
Earnings Date	Mar 10, 2026

About BioNTech SE

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies to treat cancer and infectious diseases in Germany. The company develops BNT111, which is in Phase 2 clinical trial for advance melanoma; BNT113, which is in Phase 2 clinical trial to treat head and neck squamous cell carcinoma; BNT116, which is in Phase I clinical trial for non-small cell lung cancer; BNT142, which is in phase 1/2 clinical trial for multiple solid tumors; BNT151, which is in phase 1/2 clinical trial for solid tumors; BNT152+BNT153, which is in ph...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2008
• Employees: 6,772
• Stock Exchange: Brazil Stock Exchange
• Ticker Symbol: B1NT34

Financial Performance

Financial numbers in EUR